Trial Profile
Chimeric Anti-CD20 Monoclonal Antibody (Mabthera) in Remission Induction and Maintenance Treatment of Relapsed Follicular Non-Hodgkin's Lymphoma: A Phase III Randomized Clinical Trial - Intergroup Collaborative Study.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- 26 Jul 2017 Status changed from active, no longer recruiting to completed.
- 21 Sep 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
- 02 Dec 2011 Actual end date 11 Nov 2005 added as reported by ISRCTN.